Mutant myeloid cells are believed to drive the inflammation in patients with VEXAS syndrome, as analyses have revealed activated inflammatory pathways consistent with myeloid-induced inflammation, including tumor necrosis factor (TNF), interleukin-6 (IL-6), and interferon-gamma (INF-gamma). This evidence concerns the gene IFNG and VEXAS syndrome.